openPR Logo
Press release

Aptinyx Inc. (NASDAQ: APTX) Investor Investigation over potential Wrongdoing

05-05-2020 03:20 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of investors in Aptinyx Inc. (NASDAQ: APTX) shares over potential wrongdoing at Aptinyx Inc.

An investigation on behalf of investors in Aptinyx Inc. (NASDAQ: APTX) shares over potential wrongdoing at Aptinyx Inc.

An investigation on behalf of investors in shares of Aptinyx Inc. (NASDAQ: APTX) was announced over potential breaches of fiduciary duties by certain officers and directors at Aptinyx Inc.

Investors who purchased shares of Aptinyx Inc. (NASDAQ: APTX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Aptinyx Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.

Evanston, IL based Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx Inc. completed its initial publis offering ("IPO") on June 21, 2018, offering $16.00 per share for net proceeds of $92.2 million. However, since the IPO shares of Aptinyx Inc. (NASDAQ: APTX) declined to as low as $2.96 per share on August 26, 2019.

Those who purchased shares of Aptinyx Inc. (NASDAQ: APTX) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Aptinyx Inc. (NASDAQ: APTX) Investor Investigation over potential Wrongdoing here

News-ID: 2033814 • Views: 598

More Releases from Shareholders Foundation

Bit Digital, Inc. (NASDAQ: BTBT) Investor Alert: Deadline in Lawsuit on March 22 …
A deadline is coming up on March 22, 2021 in the lawsuit filed for certain investors of Bit Digital, Inc. (NASDAQ: BTBT) over alleged securities laws violations by Bit Digital, Inc. Investors who purchased shares of Bit Digital, Inc. (NASDAQ: BTBT) have certain options and there are strict and short deadlines running. Deadline: March 22, 2021. NASDAQ: BTBT stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -
Investigation announced for Investors in Sogou Inc. (NYSE: SOGO) over potential …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Sogou Inc. Investors who are investors in Sogou Inc. (NYSE: SOGO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NYSE: SOGO stocks follows a lawsuit filed against Sogou Inc. over alleged securities laws violations.
Lawsuit filed for Investors in shares of Apache Corporation (NASDAQ: APA)
An investor, who purchased shares of Apache Corporation (NASDAQ: APA), filed a lawsuit over alleged Securities Laws violations by Apache Corporation. Investors who purchased shares of Apache Corporation (NASDAQ: APA) have certain options and for certain investors are short and strict deadlines running. Deadline: April 26, 2021. NASDAQ: APA investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. Houston, TX based Apache Corporation, an independent energy company,
Deadline on March 16th coming up in Lawsuit for Investors in Penumbra, Inc. (NYS …
A deadline is coming up on March 16, 2021 in the lawsuit filed for certain investors of Penumbra, Inc. (NYSE: PEN) over alleged securities laws violations by Penumbra, Inc. Investors who purchased shares of Penumbra, Inc. (NYSE: PEN) have certain options and there are strict and short deadlines running. Deadline: March 16, 2021. NYSE: PEN stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. According to the

All 5 Releases


More Releases for Aptinyx

Fibromyalgia Treatment Market To be lead by Eli Lilly and Company, Pfizer, Inc., …
Fibromyalgia Treatment Market report provides a thoroughly researched abstract of the key players with considerable shareholdings at a global level regarding demand, sales, and income by providing better products and services. Research Report outlines a forecast for the Fibromyalgia Treatment market between 2020 and 2027. In terms of value, the Fibromyalgia Treatment industry is expected to register a steady CAGR during the forecast period. The report offers a systematic presentation of
Fibromyalgia Therapeutics Market 2020 To See Strong Growth Including Key Players …
A recent report published by QMI on fibromyalgia therapeutics market is a detailed assessment of the most important market dynamics. After carrying out thorough research of fibromyalgia therapeutics market historical as well as current growth parameters, business expectations for growth are obtained with utmost precision. The study identifies specific and important factors affecting the market for fibromyalgia therapeutics during the forecast period. It can enable manufacturers of fibromyalgia therapeutics to
Chemotherapy Induced Peripheral Neuropathy Treatment Market Business Opportuniti …
An analysis of Chemotherapy Induced Peripheral Neuropathy Treatment Market has been provided in the latest report launched by UpMarketResearch.com that primarily focuses on the market trends, demand spectrum, and future prospects of this industry over the forecast period. Furthermore, the report provides a detailed statistical overview in terms of trends outlining the geographical opportunities and contributions by prominent industry share contenders. Click Here To Access PDF Sample Copy @ https://www.upmarketresearch.com/home/requested_sample/51736 Moreover, the
Post-Traumatic Stress Disorder (PTSD) Pipeline Review, H1 2019 by: Actinogen Med …
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2019. Summary: Post-traumatic stress disorder (PTSD) is a mental health condition that's triggered by a terrifying event either experiencing it or witnessing it. Symptoms include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants, anti-anxiety and cognitive therapy. Report Highlights: Post-Traumatic Stress Disorder (PTSD) market based on elite players, present, past and futuristic data which will offer
Chemotherapy Induced Peripheral Neuropathy Treatment Market 2019 |by Trends Anal …
MarketResearchNest.com published an Exclusive Research Report on “Global Chemotherapy Induced Peripheral Neuropathy Treatment Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024” that highlights the in-depth market analysis and covers significant data with future prospects of the market. CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle
Chemotherapy Induced Peripheral Neuropathy Treatment Market Outlook and Forecast …
The “Global Chemotherapy Induced Peripheral Neuropathy Treatment Analysis to 2025” is a specialized and in-depth study of the Chemotherapy Induced Peripheral Neuropathy Treatment industry with a focus on the global market trend. The report aims to provide an overview of global Chemotherapy Induced Peripheral Neuropathy Treatment with detailed market segmentation by component, type, application and geography. The global Chemotherapy Induced Peripheral Neuropathy Treatment market is expected to witness high growth